Lee, Sujin <br/><br/>
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jul 2010 
 - 1073-81 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-010-0834-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Female<br/>Male<br/>Mammary Neoplasms, Experimental--drug therapy<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Transgenic<br/>Oligodeoxyribonucleotides--administration & dosage<br/>Pyrazines--administration & dosage<br/>Rats<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--agonists<br/>TNF-Related Apoptosis-Inducing Ligand--administration & dosage<br/>Toll-Like Receptor 9--agonists<br/>Treatment Outcome